Article Details

Junshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for ...

Retrieved on: 2021-03-03 17:03:45

Tags for this article:

Click the tags to see associated articles and topics

Junshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for .... View article details on HISWAI: https://pipelinereview.com/index.php/2021030377580/Antibodies/Junshi-Biosciences-and-Coherus-BioSciences-Announce-Initiation-of-Rolling-Submission-of-BLA-for-Toripalimab-to-the-U.S.-FDA-for-the-Treatment-of-Nasopharyngeal-Carcinoma.html

Excerpt

Toripalimab is the first anti-PD-1 monoclonal antibody developed in China with a BLA submission to the FDA in process. In February 2021, Junshi ...

Article found on: pipelinereview.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up